In every type of financing, from IPOs and follow-on public offerings to private placements and venture capital rounds, the med-tech industry produced more money and completed more financings in 2018 than the prior year, reflecting the same significant jump in activity seen with its biopharma counterpart. What is different, however, is that med tech experienced a 38.43 percent increase in amount raised year-over-year, whereas biopharma showed a 29.64 percent increase.
Biopharma licensing deals signed in 2018 climbed to 1,364 and have a projected value of $119.54 billion, a four-year high for an industry still riding the immuno-oncology wave.
Biopharma licensing deals signed in 2018 climbed to 1,364 and have a projected value of $119.54 billion, a four-year high for an industry still riding the immuno-oncology wave.
Biopharma licensing deals signed in 2018 climbed to 1,364 and have a projected value of $119.54 billion, a four-year high for an industry still riding the immuno-oncology wave.
Favorable phase II data with N-methyl-D-aspartate (NMDA) receptor antagonist AXS-05 sent Axsome Therapeutics Inc.'s shares skyrocketing more than 200 percent on Monday, and offered new hope for an estimated 16 million major depressive disorder (MDD) patients in the U.S.
More than a third of biopharma drugs issued complete response letters (CRLs) by the FDA in 2016 later received full approval, within three to 21 months. While some investors perceive the dreaded CRL as a death sentence, as evidenced by their quick stock sell-offs, BioWorld data indicate it is sometimes merely a hiccup corrected in time.
More than a third of biopharma drugs issued complete response letters (CRLs) by the FDA in 2016 later received full approval, within three to 21 months. While some investors perceive the dreaded CRL as a death sentence, as evidenced by their quick stock sell-offs, BioWorld data indicate it is sometimes merely a hiccup corrected in time.
Series A financings are continuing their record pace, with five additional companies raising a combined total of $139 million, placing 2018 at the top for most venture capital money ever flowing into early stage companies, and doubling the amount raised one year prior: $5.4 billion vs. $2.6 billion.
For the first time in biopharma history, IPO values have crested the stalwart year of 2000, with companies raising a total of $7.44 billion globally by mid-October.
Dealmaking for the biopharma industry has continued its steady climb through the third quarter of 2018, completing 18 percent more deals that in total are worth 25 percent more than they were this time last year.
